by 
Human immunoglobulin (pH4) for intravenous injection is a medication derived from human blood plasma that is administered intravenously to patients. It contains immunoglobulin G (IgG) antibodies and is used to treat certain autoimmune and inflammatory disorders and immunodeficiencies. Some common uses include primary immunodeficiency, chronic inflammatory demyelinating polyneuropathy (CIDP), Guillain-Barré syndrome (GBS), idiopathic thrombocytopenic purpura (ITP), and Kawasaki disease.
The global human immunoglobulin market is estimated to be valued at US$ 2,055.76 Mn in 2023 and is expected to exhibit a CAGR of 16% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Dynamics
Rise in autoimmune disorders: One of the key factors driving growth of the human immunoglobulin market is the rising prevalence of various autoimmune and inflammatory disorders globally that require immunoglobulin therapy. Autoimmune diseases occur when the immune system mistakenly attacks and destroys healthy body tissues. Common autoimmune disorders include rheumatoid arthritis, systemic lupus erythematosus, ulcerative colitis, Crohn’s disease, multiple sclerosis, and others. According to a report by the American Autoimmune Related Diseases Association (AARDA), over 50 million Americans are affected by autoimmune diseases each year. This growing patient pool is expected to fuel demand for human immunoglobulin therapy over the forecast period.
Flourishing intravenous injection segment: Within the overall human immunoglobulin market, the intravenous injection segment accounts for the largest revenue share, owing to benefits such as faster absorption compared to subcutaneous administration. Intravenous immunoglobulin therapy is increasingly preferred by physicians and patients alike over other routes of administration due to its effectiveness in conditions requiring prompt intervention such as ITP and CIDP. This is expected to boost growth of the human immunoglobulin (pH4) for intravenous injection market segment over the forecast period.
Segment Analysis
The global human immunoglobulin (pH4) for intravenous injection market can be segmented on the basis of application and end user. Based on application, the market is dominated by primary immunodeficiency segment, which accounts for more than 50% share of the overall market. Primary immunodeficiency condition leads to recurring infections, thus fueling the demand for immunoglobulin replacement therapy.
PEST Analysis
Political: The regulations for approval of new immunoglobulins are stringent. However, favorable government policies to improve healthcare infrastructure is supporting market growth.
Economic: Rising disposable incomes in developing countries is increasing healthcare spending. This is positively impacting the market.
Social: Increasing awareness about primary immunodeficiency and associated conditions is driving more patients to seek diagnosis and treatment.
Technological: Advances in purification techniques are helping manufacturers develop more effective and safer immunoglobulin products. This is expanding the market potential.
Key Takeaways
The global human immunoglobulin (pH4) for intravenous injection market is expected to witness high growth over the forecast period of 2023 to 2030. The North America region currently dominates the market aided by presence of major players and high healthcare spending.
Regional analysis
North America commands largest share of over 40% of the global market driven by rising prevalence of primary immunodeficiency disorders and favorable reimbursement policies. The US contributes significantly to the regional market growth.
Key players
Key players operating in the human immunoglobulin (pH4) for intravenous injection market are Major players operating in the point of care infectious disease diagnostics market include Danaher Corporation, Abbott Laboratories, Alcon Laboratories, Inc., Hoffman-La Roche Ltd., Becton, Dickinson, and Company, Trinity Biotech Plc, AccuBioTech Co., Ltd. and Cardinal Health, Inc. CSL Behring commands leading share owing to its diverse immunoglobulin product portfolio
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
